SCHEDULE: Morgan Stanley Discloses 5.4% Stake in UroGen Pharma

Morgan Stanley has disclosed a 5.4% beneficial ownership stake in UroGen Pharma Ltd., holding 2,488,299 ordinary shares.

Summary

• Morgan Stanley, a Delaware-based entity, has reported beneficial ownership of 2,488,299 ordinary shares of UroGen Pharma Ltd.
• This ownership represents 5.4% of UroGen Pharma Ltd.'s outstanding ordinary shares.
• The event requiring this filing occurred on June 30, 2025.
• Morgan Stanley holds shared voting power over 2,463,149 shares and shared dispositive power over 2,488,299 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: A Schedule 13G filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or outlook. It is a neutral regulatory compliance document.

Industry Context

This filing indicates a significant institutional investment by Morgan Stanley in UroGen Pharma Ltd., a company in the biopharmaceutical sector. Such disclosures are common for large financial institutions managing diverse portfolios and reflect their passive investment positions.

Stakeholder Impact

• Shareholders: Increased institutional ownership may be viewed positively, indicating confidence from a major financial institution, though this is a passive investment.

Key Dates

Keywords

UroGen Pharma, Morgan Stanley, Beneficial Ownership, SEC Filing, Schedule 13G, Ordinary Shares, Institutional Ownership, Biopharma